RELEX-SOLUTIONS
3.1.2024 09:31:35 CET | Business Wire | Press release
Today, RELEX Solutions, provider of unified supply chain and retail planning solutions, announced it has acquired Optimity, a supply chain planning and optimization provider. The acquisition will bolster the RELEX retail and supply chain platform with daily production planning, optimization and production scheduling capabilities which are crucial for the end-to-end consumer goods value chain.
“The consumer goods industry is incredibly dynamic and complex. Acquiring Optimity will seamlessly link downstream demand with upstream planning, so consumer goods companies can more accurately predict consumer demand, optimize production plans and schedules, adjust inventory levels, and respond quickly to market changes or unexpected disruptions,” said Mikko Kärkkäinen, co-founder and group CEO, RELEX. “This acquisition also further accelerates our vision towards an adaptive, autonomous and synchronized supply chain unifying demand and supply planning decisions in one platform to minimize all wasted cost and product. We warmly welcome the Optimity team to RELEX.”
Optimity, with global headquarters in Sweden and offices around the world, offers a broad supply chain planning and optimization solution specifically for manufacturers and distributors. Optimity enables customers to make optimal supply chain decisions from strategic levels to detailed production scheduling. Their offerings include demand planning, production planning and scheduling, supply planning, distribution planning, inventory optimization, and S&OP. With 80+ customers across the food and beverage, and complex manufacturing industries, Optimity’s experience augments RELEX’s expertise across retail and consumer goods markets.
The acquisition brings together a highly complementary offering between the two organizations, enabling RELEX to extend and deepen its production planning and supply chain optimization capabilities, such as synchronized daily production planning, optimization and scheduling in the food & beverage and manufacturing sector.
New or expanded capabilities within the RELEX unified retail and supply chain planning platform from Optimity include:
- Production planning: Create optimized production plans from up-to-date forecasts to balance operational costs and flexibility while considering production restrictions, material constraints and business priorities.
- Production scheduling: Generate and manage optimized production schedules built around constraints to reduce changeover time and bolster manufacturing efficiency.
- Network balancing: Rectify imbalances in complex distribution networks to minimize risks, reduce costs, and boost operational efficiency.
- Distribution planning: Gain complete distribution network visibility to make smarter, proactive decisions aligned with business objectives and customer service goals.
- Purchase planning: Balance supply-side complexity with end-to-end visibility to pinpoint the most efficient and profitable way to fulfill demand plans and customer obligations.
“Our depth in some of the most complex consumer goods industries like bakery, ready-made meals, protein production and industrial manufacturing complements the vast understanding of consumer demand that RELEX has, based on their impressive expertise managing more than $700 billion of demand in grocery alone,” said Christer Liden, CEO, Optimity. “We are thrilled to join the RELEX team and further optimize the consumer goods value chain together.”
To learn more about the acquisition, please visit this page.
About RELEX
RELEX Solutions helps retailers and consumer brands drive profitable growth across all sales and distribution channels by maximizing customer satisfaction and minimizing operative costs. Our market-leading, unified supply chain and retail planning platform helps retailers and consumer goods companies align and optimize demand, merchandising, supply chain, and operations planning across the end-to-end value chain. We drive record-high product availability, increased sales, improved sustainability, and the best return on investment in inventory, space, workforce, and capacity. Leading brands like Dollar Tree and Family Dollar, Stokke, Rite Aid, Sprouts Farmers Market, AutoZone, and PetSmart trust RELEX to optimize their supply chain and retail planning. Go to relexsolutions.com for more.
About Optimity
For nearly two decades, Optimity has challenged the supply chain planning space. Optimity has provided companies with user-friendly yet powerful planning software to optimize even the most intricate supply chains. We believe every supply chain can maximize profits effortlessly with the right tools. Optimity delivers a comprehensive solution, covering strategic optimization to detailed production scheduling. Our expert team, boasting years of industry knowledge, ensures success in every project. Supply chain planning is pivotal for manufacturing and distribution, and Optimity excels in delivering solid solutions for complex supply chains. Our integrated planning tool ensures profitability, simplifying processes for sustainable growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103171132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom